Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids

• US 9,757,351 B2
• Filed: 03/11/2016
• Issued: 09/12/2017
• Est. Priority Date: 11/20/2006
• Status: Active Grant

• Current Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Original Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Inventors: Wang, Lixiao
• Primary Examiner(s): ZISKA, SUZANNE E
• Application Number:
  US15/067,734
• Publication Number:
  US 20160263076A1
• Time in Patent Office: 550 Days
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61L 2300/22 Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 29/08 Materials for coatings
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/08 Materials for coatings
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61M 2025/1031 Surface processing of balloon members, e.g. coating or deposition; Mounting additional parts onto the balloon member's surface
• CPC Class Codes: A61M 2025/105 having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
• CPC Class Codes: A61M 25/10 Balloon catheters A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02; inflatable balloons for placing stents or stent-grafts A61F2/958 ; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00
• CPC Class Codes: A61M 25/1029 Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
• CPC Class Codes: A61M 25/104 used for angioplasty

Abstract

The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, at least one of an oil, a fatty acid, and a lipid, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, a part that has an affinity to the therapeutic agent by charge, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is at least one of a surfactant and a chemical compound. In further embodiments, the chemical compound is water-soluble.

Claims

1. A balloon catheter for delivering a therapeutic agent to a target site of a blood vessel, the balloon catheter comprising a coating layer overlying an exterior surface of a balloon of the balloon catheter, the coating layer comprising a therapeutic agent and an additive,

wherein:

the balloon catheter is a scoring balloon catheter;

the therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, beta-lapachone, biologically active vitamin D, and combinations thereof; and

the additive comprises gluconolactone, glucoheptonolactone, glucooctanoic lactone, or combinations thereof.

2. The balloon catheter of claim 1, wherein the coating layer is dried.

3. The balloon catheter of claim 1, wherein the additive comprises gluconolactone.

4. The balloon catheter of claim 1, wherein the additive is gluconolactone.

5. The balloon catheter of claim 1, wherein:

the coating layer consists essentially of the therapeutic agent and the additive;

the therapeutic agent is paclitaxel; and

the additive is gluconolactone.

6. The balloon catheter of claim 1, wherein:

the coating layer consists of the therapeutic agent and the additive;

the therapeutic agent is paclitaxel;

the additive is gluconolactone.

7. The balloon catheter of claim 1, wherein the additive is glucoheptonolactone.

8. The balloon catheter of claim 1, wherein the additive is glucooctanoic lactone.

9. The balloon catheter of claim 1, wherein the additive further comprises gulonic acid lactone.

10. The balloon catheter of claim 1, wherein the additive further comprises mannonic acid lactone.

11. The balloon catheter of claim 1, wherein the additive further comprises ribonic acid lactone.

12. The balloon catheter of claim 1, wherein the therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, and combinations thereof.

13. The balloon catheter of claim 1, further comprising an adherent layer between the exterior surface of the balloon and the coating layer.

14. The balloon catheter of claim 1, further comprising a top layer overlying the coating layer.

15. The balloon catheter of claim 1, wherein the concentration of the therapeutic agent in the coating layer is from 1 μ

g/mm² to 20 μ

g/mm².

16. The balloon catheter of claim 1, wherein the concentration of the therapeutic agent in the coating layer is from 2 μ

g/mm² to 6 μ

g/mm².

17. The balloon catheter of claim 1, wherein the ratio by weight of the additive to the therapeutic agent in the coating layer is from about 0.1 to 5.

18. The balloon catheter of claim 1, wherein the coating layer further comprises at least one oil chosen from soybean oil, vegetable oil, flower oil, animal oil, butterfat, coconut oil, palm oil, olive oil, peanut oil, or fish oil.

19. The balloon catheter of claim 1, wherein the coating layer further comprises at least one fatty acid chosen from butanoic acid, hexanoic acid, octanoic acid, decanoic acid, dodecanoic acid, tetradecanoic acid, hexadecanoic acid, octadecanoic acid, octadecatrienoic acid, eicosanoic acid, eicosenoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, tocotrienol, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, behenic acid, erucic acid, lignoceric acid.

20. The balloon catheter of claim 1, wherein the coating layer further comprises at least one lipid chosen from cardiolipin, phosphatidylglycerol, phosphatidic acid, phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, phosphatidylserine, phosphatidylinositol, dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, or distearoylphosphatidylcholine.